Valuation: AstraZeneca PLC

Market Cap 263B 230B 212B 195B 368B 25,307B 376B 2,533B 996B 12,394B 987B 965B 42,668B P/E 2026 *
21.2x
P/E 2027 * 18.6x
Enterprise Value 282B 246B 227B 210B 395B 27,156B 404B 2,718B 1,069B 13,300B 1,059B 1,036B 45,784B EV / Sales 2026 *
4.46x
EV / Sales 2027 * 4.11x
Free-Float
96.63%
Yield 2026 *
1.97%
Yield 2027 * 2.08%

Last Transcript: AstraZeneca PLC

Manager TitleAgeSince
Chief Executive Officer 66 01/10/2012
Director of Finance/CFO 52 01/08/2021
Compliance Officer - 01/01/2023
Director TitleAgeSince
Director/Board Member 70 06/04/1999
Director/Board Member 66 01/10/2012
Director/Board Member 65 27/04/2017
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--% - - 263B
+0.85%-0.80%+54.84%+163.70% 1,051B
+1.23%-1.53%+55.26%+59.07% 609B
+0.04%+2.58%+32.96%+88.75% 450B
+0.78%-0.71%+30.04%+24.61% 330B
+1.41%+0.58%+33.92%+47.20% 284B
-1.76%+2.37%-22.19%-38.45% 223B
-1.42%+0.80%+22.81%+60.77% 198B
-1.48%+3.43%+23.42%+73.31% 167B
-0.36%+3.64%+1.91%-30.15% 143B
Average +0.10%+1.15%+25.89%+49.87% 383.89B
Weighted average by Cap. +0.30%+0.32%+37.46%+81.29%

Financials

2026 *2027 *
Net sales 63.21B 55.24B 50.97B 46.99B 88.56B 6,087B 90.53B 609B 240B 2,981B 237B 232B 10,263B 66.79B 58.37B 53.86B 49.64B 93.57B 6,432B 95.65B 644B 253B 3,150B 251B 245B 10,844B
Net income 12.43B 10.86B 10.03B 9.24B 17.42B 1,197B 17.8B 120B 47.13B 586B 46.69B 45.66B 2,019B 13.94B 12.18B 11.24B 10.36B 19.53B 1,342B 19.96B 134B 52.84B 657B 52.34B 51.19B 2,263B
Net Debt 19.2B 16.77B 15.48B 14.27B 26.89B 1,849B 27.49B 185B 72.77B 905B 72.09B 70.51B 3,117B 11.9B 10.4B 9.6B 8.85B 16.68B 1,146B 17.05B 115B 45.12B 561B 44.7B 43.72B 1,933B
Logo AstraZeneca PLC
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows: - product sales (99.8%). Net sales break down by treatment area between oncology (42.6%), cardiovascular, renal and metabolic diseases (23%), respiratory and autoimmune diseases (14.7%), and other (19.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases); - collaboration revenue (0.2). Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (22.9%), the United States (40.8%), Americas (6.1%) and Africa/Asia/Australia (22.8%).
Employees
-
Trader
Investor
Global
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
24
Last Close Price
169.43USD
Average target price
212.11USD
Spread / Average Target
+25.19%

Quarterly revenue - Rate of surprise